Author:
Li Lin,Hu Xiaoyan,Nkwocha Jewel,Sharma Kanika,Zhou Liang,Grant Steven
Funder
National Cancer Institute
Leukemia & Lymphoma Society
National Institutes of Health
Subject
Cancer Research,Oncology,Hematology
Reference15 articles.
1. Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy;Aleshin;Blood Adv.,2018
2. Treatment of relapsed/refractory acute myeloid leukaemia in adults;Rashidi;Br. J. Haematol.,2018
3. Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL;Martin;Blood,2022
4. M.B. Pappalardi, K. Keenan, M. Cockerill, W.A. Kellner, A. Stowell, C. Sherk, K. Wong, S. Pathuri, J. Briand, M. Steidel, P. Chapman, A. Groy, A.K. Wiseman, C.F. McHugh, N. Campobasso, A.P. Graves, E. Fairweather, T. Werner, A. Raoof, R.J. Butlin, L. Rueda, J.R. Horton, D.T. Fosbenner, C. Zhang, J.L. Handler, M. Muliaditan, M. Mebrahtu, J.P. Jaworski, D.E. McNulty, C. Burt, H.C. Eberl, A.N. Taylor, T. Ho, S. Merrihew, S.W. Foley, A. Rutkowska, M. Li, S.P. Romeril, K. Goldberg, X. Zhang, C.S. Kershaw, M. Bantscheff, A.J. Jurewicz, E. Minthorn, P. Grandi, M. Patel, A.B. Benowitz, H.P. Mohammad, A.G. Gilmartin, R.K. Prinjha, D. Ogilvie, C. Carpenter, D. Heerding, S.B. Baylin, P.A. Jones, X. Cheng, B.W. King, J.I. Luengo, A.M. Jordan, I. Waddell, R.G. Kruger, M.T. McCabe, Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia, Nat Cancer, 2 (2021) 1002–1017.
5. Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches;Brunner;Clin. Adv. Hematol. Oncol.,2018